If SKS felt squalamine was a bust, they could have waited 3 weeks and merged with Ohr for a better deal in terms of equity. It's silly not to consider the timing of these 3 top clinicians business decision. SKS was not going to fail in 3 weeks or 3 months. They merged early to get a better equity arrangement in Ohr
....that the squalamine drops are effective in reducing neovascularization. We will soon know how effective 2 x per day is for wet amd, but my guess is that injections are reduced by about 80% or higher on average
I started posting on the other board once I became a distracting target on this one. But I still read the yahoo board, though will not post much on it again. As cutis stated, I am totally bullish now that the SKS purchased has gone through and the recent stakes reported by Millenium management verify that the street now takes OHRP seriously.
I would like to have about 3 other moderators of this site so if rich, bio, stuart ..etc are interested let me know.. Rude posts will be deleted and posters who have a pattern of rudeness are going to be banned.
hey prince; at least tell me you plan to cover your shorts before news comes out or are you comfortable taking that kind of risk?
And each investor has to decide, based on some formula such as the Kelly criteria, what fraction to invest and that can change from day to day. And then only PUT AT RISK what you can afford to lose. In an uptrend, risk is small, but in a downtrend, risk is large.
Now optimist you may be right and the drops may not work at all. .The statement that was on Dr. Kat's website perhaps is what drove the stock up. But the price of a share was about $6.80 or so when I pointed it out EXACTLY THE SAME PRICE NOW.
What happened is that a quiet yahoo message board with about 10 regular posters suddenly had a bunch of new emotional investor joined in, such as yourself. And then as the price rose to giddy heights, shorts came around knowing that these new investors could be knocked out of their positions.
Now we are back to the price of a share before the Dr. Katz news leak came out. The company has sold nearly 2 mlllon shares at a much higher price thanks to the interest of people such as yourself who joined in late. So thanks opti, for having funded Ohr
Squalamine data comes out in 4 to 5 weeks. I had hoped it would be sooner, but so be it. Only at that time will you, me, and the market know FOR SURE whether squalamine drops work or not.
Now the company sold 1.8 million shares to well heeled investors at $10 and given themselves 1.5 million stop options at $10+. So perhaps the company and well heeled investors were fooled too? LOL
I think the bottom is in, but it's going to take consolidation at this level for the next few days.. Since the shelf hit us, rational thinking is out and emotional thinking is in which is normal for everybody when they see a train coming at them.
As I've said, the market needs more data and Ohr has given us only 1 patient which does not give scientific validity to the statement 'squalamine drops work' . That's the crux of the problem. More data will do wonders for this stock. Because more data means verifiable science has been done.
And valid scientific data that rival drops FAIL is as important if not more important. There are a hundreds of TKI's and the market may think that one of them will work eventually. So far pazopanib and the other one I found both failed; they have properties similar to Panoptica but different and if they both failed even though they differ in solubility, lipophillicity, hydrophillicity, IC-50 different for a whole host of vegf, pdgf, ..;etc/ receptors.
So two drugs of the same class with different properties both failed. Now theoretically if they could stick in the eye, they would work. They would have worked orally. But neither can stick and the investing in Squalamine thesis is that only squalamine can stick. But that cannot be proven, unless the hydrodynamics of the choroid are understood perhaps. Each contender has to be knocked down, leaving squalamine as the only survivor. So Ohr's valuation will increase over years as this thesis is tested..
This move down was triggered by the shelf and then the shelf SET OFF technical sell signals. No bad news came out. As has been mentioned, people bought on margin and had to sell as this came down. As they sold, the price dropped and AF's poisoned pen pushed did it's work.
PanOptica's announcement of another TKI drop drove this stock down as it got a huge private placement, something like 75 million dollars since inception. And Guyor is a big name.
regarding the dose change, when I said "other board members" I am referring to doctors on the Ohr medical advisory board .